Sun Pharma will market the 10 mg, 20 mg Vonoprazan tablets under the brand name Voltapraz. Cipla said it will commercialise the drug in India under its own trademark brands.
Vonoprozan (oral tablets) is a novel potassium-competitive acid blocker (P-CAB), used for the treatment of related disorders – Gastroesophageal Reflux Disease (GERD).
Vonoprozan will help in treating disorders such as erosive oesophagitis, gastric ulcer, duodenal ulcer, peptic ulcer, gastroesophageal reflux, reflux oesophagitis and Helicobacter pylori eradication.
GERD is common in India irrespective of geographical location. Prevalence of GERD in Indian population ranges from 5% to 28.5%. Risk factors for GERD include age, body mass index (BMI), non-vegetarian diet, tea or coffee intake, tobacco, and alcohol consumption.
In November 2023, Vonoprazan was approved by the US FDA for healing and maintenance of healing of all grades of Erosive esophagitis and relief of heartburn associated with Erosive esophagitis and in combination with amoxicillin and clarithromycin or amoxicillin alone for the treatment of Helicobacter pylori (H. pylori) infection in adults.Vonoprazan was discovered and developed by Takeda. With a novel mechanism of action, Vonoprazan inhibits the binding of potassium ions to H+ K+ ATPase (proton pump) in gastric parietal cells in the stomach thereby suppressing basal and stimulated gastric acid secretion.
The drug is approved in India for treatment of adults with Reflux esophagitis and other acid peptic disorders.
